MRMingyang Ren

Mingyang Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mingyang Ren has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Xianhong Yang

    Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, 310014, People's Republic of China

    3 shared publications
  • Yan Teng

    Department of Dermatology Center for Plastic and Reconstructive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College Hangzhou China

    3 shared publications
  • Wei Lu

    Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, 310014, People's Republic of China

    2 shared publications
  • Xiaohua Tao

    Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, 310014, People’s Republic of China

    2 shared publications
  • Yang Ding

    Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou, 310014, People’s Republic of China

    2 shared publications
  • Li Kang

    Department of Dermatology BenQ Medical Center The Affiliated BenQ Hospital of Nanjing Medical University Nanjing Jiangsu People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Challenges in the Treatment of Xanthoma Disseminatum: Improvement in Disfiguring Facial Lesions with Cladribine and Brief Updated Literature Review

    by Mingyang Ren, Li Kang

    Xanthoma disseminatum (XD) is a rare normolipidemic mucocutaneous xanthomatosis that falls within the spectrum of cutaneous non-Langerhans cell histiocytosis. The management of XD poses significant challenges due to the limited availability of clinical data. Here, we report a case of XD with disfiguring facial involvement that showed marked improvement following treatment with cladribine. The patient tolerated the treatment well, with no significant adverse effects observed except for a transient decrease in white blood cell count, which normalized after symptomatic treatment with appropriate oral medications. Additionally, we provide an updated review of the literature on the use of cladribine in XD. Through this case report and literature review, we aim to underscore both the potential benefits and limitations of cladribine therapy for patients with XD. Furthermore, we emphasize the critical importance of effective interdisciplinary collaboration between dermatology and oncology for the optimal management of this condition.


  • Open Access

    Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report

    by Yan Teng, Mingyang Ren, Xianhong Yang, Wei Lu, Xiaohua Tao

    Background: Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being the most commonly affected site. Its treatment depends on the site(s) of mucosal involvement and disease severity. Patients and Methods: A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile. Results: The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement. Conclusion: Abrocitinib is a promising agent for the treatment of MMP with oral involvement.


  • Open Access

    Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report

    by Mingyang Ren, Xianhong Yang, Yan Teng, Wei Lu, Yang Ding, Xiaohua Tao

    Granulomatous rosacea (GR) is a rare inflammatory skin disease characterized by persistent, hard, yellow, brown, red, or flesh-colored papules, plaques, or nodules on the face. Limited data are available on patients treated for GR, with only case reports and case series published. Herein, we describe the case of a 53-year-old woman who presented to the hospital with persistent red to brown and pink patches on both cheeks accompanied by a burning sensation for one month. Histopathological examination of a cutaneous biopsy revealed granulomatous inflammation in focal areas. Both acid-fast and Periodic acid-Schiff staining were negative. The patient was diagnosed with GR based on her clinical presentation and laboratory test results. She was treated with abrocitinib, a JAK-1 inhibitor, for 20 weeks. This resulted in substantial improvement in her rash and the associated burning sensation. Subsequent follow-up visits indicated no adverse effects or relapses. Additionally, a literature review was conducted to compare with the current case, which concluded that abrocitinib is a viable treatment option for GR, exhibiting a relatively high safety profile with minimal side effects.


  • Open Access

    A Case of Perioral Dermatitis Successfully Treated with Abrocitinib

    by Yan Teng, Mingyang Ren, Yang Ding, Xianhong Yang, Yibin Fan, Xiaohua Tao

    Perioral dermatitis (POD) is a chronic inflammatory skin disease that primarily affects females between the ages of 16 and 45. Conventional therapies face the challenge of limited efficacy and a high recurrence rate. In this report, we present the case of a 26-year-old male patient with POD who was successfully treated using the Janus kinase (JAK) inhibitor, abrocitinib. This treatment exhibited both good efficacy and safety. Abrocitinib, as a JAK inhibitor, holds promise as a potential therapy for cases of POD that might be resistant to conventional therapies.